Sino Biopharm stock gets a higher Bank of America target
Published on 10/05/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sino Biopharm stock (ISIN KYG8167W1380) was last at HKD 5.55 on HKEX on October 5, 2026, at 4:08 p.m. HKT, down 0.54 percent from the prior close. The latest analyst action came from Bank of America Securities, which raised its target from HKD 7.3 to HKD 7.4 and reiterated a Buy rating on October 2, 2026, according to Futunn.
Bank target moves to HKD 7.4
The revised target lies 33.3 percent above the HKD 5.55 stock price. Bank of America linked the change to Sino Biopharm's strategic biosimilar partnership with STADA, which covers commercialization rights for the pembrolizumab biosimilar TQB3570 in Europe and other markets, while Sino Biopharm retains development, manufacturing and supply responsibilities, Futunn reported on October 2, 2026.
The agreement includes an upfront payment and up to EUR 53 million in development, regulatory and sales milestones, alongside a double-digit profit share. The partnership gives the company an additional international commercialization channel while keeping manufacturing and supply within the group.
First-half revenue rises 10.6 percent
Sino Biopharm reported revenue of RMB 19.44 billion for the six months ended June 30, 2026, up 10.6 percent from the comparable period. Profit attributable to equity holders reached RMB 3.43 billion, up 1.4 percent, while underlying profit rose 8.1 percent to RMB 3.34 billion, according to Futunn on September 24, 2026.
The earnings mix showed a faster shift toward innovative products. Revenue from innovative drugs and out-licensing reached RMB 8.79 billion in the first half, up 44.3 percent year over year and equal to 45.2 percent of total revenue, while research and development spending reached RMB 3.29 billion.
Stock sits below its yearly midpoint
At HKD 5.55, the stock is HKD 2.99 below its 52-week high of HKD 8.54 and HKD 1.36 above its 52-week low of HKD 4.19. The range places the shares closer to the lower end of the yearly band, making the analyst target and the innovation-led revenue mix the key valuation reference points.
HKD 5.55 last price on October 5
Sino Biopharm stock was last at HKD 5.55 on HKEX on October 5, 2026, at 4:08 p.m. HKT, with a daily change of minus 0.54 percent and volume of 20,522,648 shares.
Sino Biopharm stock key data
- Company: Sino Biopharmaceutical Limited
- ISIN: KYG8167W1380
- Ticker: 1177
- Trading venue: HKEX
- Price (as of October 5, 2026, 4:08 p.m. HKT): HKD 5.55
- Market capitalization: HKD 98.9 billion (as of October 5, 2026)
- 52-week range: HKD 4.19-8.54 (as of October 5, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals, Biotechnology and Life Sciences
